Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized eculizumab infusion spacing in adults with atypical hemolytic uremic syndrome in remission
2020-003565-19Phase 3Completed
- Sponsor
- CHRU Tours
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of eculizumab in atypical hemolytic uremic syndrome (aHUS) (2 arms), sponsored by CHRU Tours. Primary endpoint: Cost per QALY gained at 18 months. Started Feb 2021; status: completed.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2020-003565-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003565-19.